Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer 10 August 2022 | Press release
Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation 5 April 2022 | Press release
Graeme Smith, CSO and Helen Robinson, VP Biology attending the 5th Digital DDR, ATR, & PARP Summit – 25/26 January 2022 25 January 2022 | Conferences
Listen to our CEO and CSO talk at the Northland Synthetic Lethality Conference – Nov 17 2021 2 December 2021 | Conferences
Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair 16 November 2021 | Press release